Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors

The results demonstrate that adequate numbers of functional DC required for clinical therapy can be generated from patients who have >1% of CD14+ monocytes in the leukapheresis product. Moreover, Ag-loaded DC can be cryopreserved and recovered without significant change in phenotype or function.